If the reduction in body weight and the improvement of glycemic control are crucial factors in determining the effects of GLP-1 on NAFLD, direct pharmacological mechanisms could also be involved. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.